chevron_left
IMS 2024
adjust
1. Highlights from IMS | Angela Dispenzieri, MD | IMS 2024 Video
bookmark_border
2. Thematic Analysis on Talquetamab and Patient Perceptions | Alexandra L. Greenwood, BSc | IMS 2024 Video
bookmark_border
3. Carfilzomib Dosing in the Real World Setting | Adeel Khan, MD | IMS 2024 Video
bookmark_border
4. New Criteria for Defining High Risk Multiple Myeloma | Gareth Morgan & Faith Davies | IMS 2024 Video
bookmark_border
5. Investigating Oral Toxicity Associated with Talquetamab in Myeloma | Rakesh Popat | IMS 2024 Video
bookmark_border
6. New IMS High Risk Multiple Myeloma Consensus Definition | Jill Corre, PharmD, PhD | IMS 2024 Video
bookmark_border
7. Treating High Risk Multiple Myeloma an Evidence-Based Approach | Katja Weisel, MD | IMS 2024 Video
bookmark_border
8. Safety and Efficacy of Cilta-Cel in RRMM: Real-World Experience | Surbhi Sidana, MD | IMS 2024 Video
bookmark_border
9. Iberdomide Maintenance Therapy after ASCT in Myeloma | Tanye Wildes, MD | IMS 2024 Video
bookmark_border
10. Current Approach for the Management of Smoldering Multiple Myeloma | Vincent Rajkumar, MD | IMS 2024 Video
bookmark_border
11. AURIGA- Dara + Len vs Len Alone as Myeloma Maintenance | Rafael Fonseca, MD | IMS 2024 Video
bookmark_border
12. Unveiling Novel Biomarkers in Myeloma: The Role of CTCs & cfDNA | Bruno Paiva, PhD | IMS 2024 Video
bookmark_border
13. Timing for Myeloma CAR-T Therapy: A Debate | Rahul Banerjee, MD and Sridevi Rajeeve, MD | IMS 2024 Video
bookmark_border
14. Should MRD Guide Myeloma Treatment? A Debate. | Rahul Banerjee, MD and Sridevi Rajeeve, MD |IMS 2024 Video
bookmark_border
15. An Update on the Use of Bispecific Antibodies in Myeloma | Mohamad Mohty, MD | IMS 2024 Video
bookmark_border
16. Future Strategies for Managing 2nd Line+ Myeloma: What’s Next? | Leo Rasche, MD | IMS 2024 Video
bookmark_border
17. Preliminary Results of Mezigdomide Combinations in RRMM Patients | Luciano Costa, MD, PhD | IMS 2024 Video
bookmark_border
18. Real world evidence with teclistamab for RRMM patients | Bea Razzo, MD | IMS 2024 Video
bookmark_border
19. Optimizing Outcomes in Early CAR-T Therapy | Luciano Costa, MD, PhD | IMS 2024 Video
bookmark_border
20. Newer Therapies for RRMM: Impact on Aging Patients | Suzanne Lentzsch, MD, PhD | IMS 2024 Video
bookmark_border
21. Clinical Trial Results for Novel Academic Anti-BCMA Myeloma CAR-T Cell | Yael Cohen, MD | IMS 2024 Video
bookmark_border
22. Talquetamab and Teclistamab in RRMM: Updated Results from RedirecTT-1 | Yael Cohen, MD | IMS 2024 Video
bookmark_border
23. MILESTONE Trial: MRD Adapted Deferral of Transplant in Dysproteinemia | Susan Bal, MD | IMS 2024 Video
bookmark_border
24. Sequencing bispecific antibodies in myeloma - BCMA or GPRC5D? | Rahul Banerjee, MD | IMS 2024 Video
bookmark_border
25. Predictors of delayed responses to teclistamab in myeloma | Rahul Banerjee, MD | IMS 2024 Video
bookmark_border
26. Update on MCARH109- a GPRC5D CAR-T Cell for Myeloma | Eric Jergens, MD | IMS 2024 Video
bookmark_border
27. Linvoseltamab Efficacy in High-Risk RRMM: LINKER-MM1 Study | Attaya Suvannasankha, MD | IMS 2024 Video
bookmark_border
28. Efficacy of Bispecifics in Black Patients in Myeloma Trials | Craig Emmitt Cole, MD | IMS 2024 Video
bookmark_border
29. HealthTree Study: Dexamethasone's Impact on Eye Health in Myeloma | Rahul Banerjee, MD | IMS 2024 Video
bookmark_border
30. Real World Data on Ide-Cel Efficacy and Side Effects Profile | Rafat Abonour, MD | IMS 2024 Video
bookmark_border
31. Phase 3 Trials & Quadruplet Therapy in Newly Diagnosed Multiple Myeloma | Bruno Costa, MD | IMS 2024 Video
bookmark_border
31. Positioning Model to Evaluate CARVYKTI in Second Line vs Later Lines | Rafael Fonseca, MD | IMS 2024 Video
bookmark_border
32. Selinexor Prior to CAR-T Cell Therapy in Myeloma | Bruno Costa, MD | IMS 2024 Video
bookmark_border
33. Using MRD Adapted Strategy (MIDAS) to guide myeloma treatment | Sagar Lonial, MD, FACP | IMS 2024 Video
bookmark_border
34. Detecting Minimal Residual Disease | Dory Abelman, PhD(c) | IMS 2024 Video
bookmark_border
35. Update on the iStopMM Study | Sigurður Kristinsson, MD, PhD | IMS 2024 Video
bookmark_border
36. Future Directions & Challenges in MM Precursor Conditions | María-Victoria Mateos, MD, PhD| IMS 2024 Video
bookmark_border
37. Overall Survival with Cilta-cel vs Standard of Care in Lenalidomide Refractory MM | María-Victoria Mateos, MD, PhD | IMS 2024 Video
bookmark_border
38. Talquetamab as a Bridging Therapy to CAR-T Treatment | Shebli Atrash, MD | IMS 2024 Video
bookmark_border
39. Talquetamab Use in Treating Relapsed Refractory Multiple Myeloma | Shebli Atrash, MD | IMS 2024 Video
bookmark_border
40. Results of a Phase 1 Clinical Trial of Belantamab Mafadotin in RRMM | Shebli Atrash, MD | IMS 2024 Video
bookmark_border
41. Strategies used to Prevent T-cell Exhaustion in Myeloma | Hermann Einsele, MD, FRCP | IMS 2024 Video
bookmark_border
42. The Current Standard of Care in the Post-Transplant Setting | Fredrik Schjesvold, MD, PhD | IMS 2024 Video
bookmark_border
43. Risk Stratification for Smoldering Myeloma | Irene Ghobrial, MD | IMS 2024 Video
bookmark_border
44. Frontline Therapy in Multiple Myeloma | Claudio Cerchione, MD | IMS 2024 Video
bookmark_border
45. Diagnosis and Monitoring Multiple Myeloma | Claudio Cerchione, MD | IMS 2024 Video
bookmark_border
46. Preventing Multiple Myeloma | Claudio Cerchione, MD | IMS 2024 Video
bookmark_border
47. Defining High Risk Multiple Myeloma | Wee Joo Chng, MD, PhD | IMS 2024 Video
bookmark_border![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
![[logo] HealthTree Foundation](https://static.healthtree.org/logo_icon_only.svg){kind=icon}